[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-383043-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-383043-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-acting-interferon-pioneering-disease-modification-of-myeloproliferative-neoplasms","Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms","","Long-acting interferon is reviewed as a disease-modifying approach for myeloproliferative neoplasms (MPNs), describing how malignant clonal activity sustains inflammatory cytokine loops and drives progression from early polycythemia vera and essential thrombocythemia to advanced myelofibrosis and leukemic transformation. Conventional MPN care mainly targets thrombosis prevention and symptom relief, whereas interferon can directly target cancer cells, modulate immunity, and inhibit JAK2-related pathogenic pathways. The review highlights improved clinical and molecular outcomes, with fewer adverse effects and less frequent dosing for long-acting forms, and outlines future research directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-acting-interferon-pioneering-disease-modification-of-myeloproliferative-neoplasms/383043/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-acting-interferon-pioneering-disease-modification-of-myeloproliferative-neoplasms/383043.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes myeloproliferative neoplasms progress over time?","Question",{"text":63,"@type":64},"MPNs involve clonal hematopoietic stem cell disorders where malignant clones produce cytokines that sustain inflammatory signaling. Progression follows a biological sequence from early PV/ET phases to advanced myelofibrosis and leukemic transformation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is interferon considered a treatment for MPNs beyond symptom control?",{"text":68,"@type":64},"Interferon can attack cancer cells directly and modulate the immune system. It also has the potential to inhibit key disease drivers such as JAK2-related mutation pathways, supporting disease-modifying potential.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantages do long-acting interferon formulations offer?",{"text":72,"@type":64},"Long-acting interferon is administered less frequently and is associated with fewer adverse effects than conventional interferon. This improved tolerability has increased interest in its use for patients with MPNs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},383043,1790659362,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nKorean J Intern Med 2023;38:810-817 [https://doi.org/10.3904/kj](https://doi.org/10.3904/kj)im.2023.333  \nLong-acting interferon: pioneering disease modification of myeloproliferative neoplasms  \nSeugYun Yoon1 and Sung-Yong Kim2  \n1Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul; 2Division of Hematology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea  \nMyeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells. The malignant clones produce cytokines that drive self-perpetuating inflammatory responses and tend to transform into more aggressive clones, leading to disease progression. The progression of MPNs follows a biological sequence from the early phases of malignancy, polycythemia vera, and essential thrombocythemia, to advanced myelofibrosis and leukemic transformation. To date, the treatment of MPNs has focused on preventing thrombosis by decreasing blood cell counts and relieving disease-related symptoms. However, interferon (IFN) has been used to treat MPNs because of its ability to attack cancer cells directly and modulate the immune system. IFN also has the potential to modulate diseases by inhibiting JAK2 mutations, and recent studies have demonstrated clinical and molecular improvements. Long-acting IFN is administered less frequently and has fewer adverse effects than conventional IFN. The current state of research on long-acting IFN in patients with MPNs is discussed, along with future directions.  \nKeywords: Interferon; Myeloproliferative neoplasm; Mutation  \nINTRODUCTION  \nMyeloproliferative neoplasms (MPNs) are a cluster of disorders marked by abnormal growth and proliferation of bone marrow myeloid progenitor cells [1] . In MPNs, stem cells produce abnormally high numbers of blood cell lineages. If the Philadelphia chromosome exists, the MPN is classified as chronic myeloid leukemia (CML) . Otherwise, it is referred to as Philadelphia chromosome-negative MPN, which includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) . MPNs are inflammatory neoplasms in which a malignant clone generates cytokines that self-perpetuate the inflammatory drive [2]. Their progression follows a biological sequence from the early phases of malignancy (ET/PV) to advanced MF and leukemic transformation. Mutations in JAK2, CALR, and MPL play significant roles in the development of MPNs, with additional mutations contributing to disease progression [3] . Symptoms of MPN, such as fatigue, headache, general weakness, and itchiness,  \nare caused by pro-inflammatory cytokines, which contribute to the development of thrombosis and hemorrhage, as well as myeloid cell proliferation [4] . The treatment goals for patients with ET and PV are managing the symptoms, preventing vascular complications, and monitoring for progression to leukemia [5] . Antiplatelet agents such as low-dose acetylsalicylic acid and cytoreductive agents such as hydroxyurea (HU) and anagrelide are the most common treatment options in Korea. In patients with PMF, JAK inhibitors such as ruxolitinib and fedratinib ameliorate symptoms, decrease splenomegaly, and correlate with an increased survival compared with conventional therapy. Currently, allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for PMF [6] . In general, patients with ET/ PV have a less severe disease burden than those with MF. The incidence of thrombosis, MF/leukemic transformation, and mortality remain low in patients with PV and ET. However, patients with ET/PV outnumber those with PMF, and their disease progression is of considerable interest.  \nCopyright © 2023 The Korean Association of Internal Medicine  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0/](http://cre","cbCaihBAeLLJc6Jr","https://ap.wps.com/l/cbCaihBAeLLJc6Jr","pdf",138888,"English","# Introduction\n## Myeloproliferative neoplasms: classification and progression\n## Treatment goals and current options\n# Interferon and rationale for long-acting therapy\n## Origins and anticancer/immunomodulatory roles of interferon\n## Challenges with conventional interferon and newer formulations\n# Mode of action of interferon","[{\"question\":\"What makes myeloproliferative neoplasms progress over time?\",\"answer\":\"MPNs involve clonal hematopoietic stem cell disorders where malignant clones produce cytokines that sustain inflammatory signaling. Progression follows a biological sequence from early PV/ET phases to advanced myelofibrosis and leukemic transformation.\"},{\"question\":\"Why is interferon considered a treatment for MPNs beyond symptom control?\",\"answer\":\"Interferon can attack cancer cells directly and modulate the immune system. It also has the potential to inhibit key disease drivers such as JAK2-related mutation pathways, supporting disease-modifying potential.\"},{\"question\":\"What advantages do long-acting interferon formulations offer?\",\"answer\":\"Long-acting interferon is administered less frequently and is associated with fewer adverse effects than conventional interferon. This improved tolerability has increased interest in its use for patients with MPNs.\"}]","Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms | PDF",1790253878]